Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin
Drug ID BADD_D01643
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms.[L8648] On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.[T689]
Marketing Status approved; investigational
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00465
MeSH ID C005419
PubChem ID 4634
TTD Drug ID D0R1DH
NDC Product Code 0023-6153; 0023-9637; 70771-1086; 70771-1087; 0615-8220; 50090-5353; 70771-1088; 17381-015; 68382-257; 0615-8219; 68382-255; 68382-256
UNII K9P6MC7092
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H31NO3
CAS Registry Number 5633-20-5
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blindness06.02.10.003; 17.17.01.0030.000113%Not Available
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Breath odour07.01.06.002--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cerebrovascular accident24.03.05.001; 17.08.01.0070.000056%
Chest discomfort08.01.08.019; 02.02.02.009; 22.12.02.002--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000085%Not Available
Colitis07.08.01.001--
Confusional state17.02.03.005; 19.13.01.0010.000198%
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.0010.000192%
Cough22.02.03.001--
Cycloplegia17.17.02.003; 06.05.03.002--Not Available
Cystitis11.01.14.001; 20.03.02.002--
Delirium19.13.02.0010.000141%
Depressed mood19.15.02.0010.000056%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.000192%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000344%
Drug hypersensitivity10.01.01.0010.001180%Not Available
Drug ineffective08.06.01.0060.002812%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 9 Pages